Because CBD oil products are mostly unregulated, there’s no guarantee that any given product contains a safe or effective level of CBD. In fact, a study published in the Journal of the American Medical Association in 2017 found that nearly 70 percent of all CBD products sold online are incorrectly labeled, and could cause serious harm to consumers. Some CBD oils may also contain incorrectly labeled amounts of THC and other compounds.
• What's the dosing? This is a confusing one for many people. "A lot of brands don't do a good job of clearly instructing their consumer on the dosing," says Chris Roth, CEO and co-founder of Highline Wellness. When thinking about dosing, also consider whether your CBD is full-spectrum or isolate: Full-spectrum could include other cannabinoids like cannabidivarin or cannabigerol (this is important, since "there's something called the 'entourage effect' when all together, they're more effective than any one of them alone," Roth explains), while isolate is 100% CBD. "Some people might only need 10 milligrams of full-spectrum CBD, but with isolate, even taking 80 or 100 milligrams might not have the same effect," he says.
CBD is an acronym for Cannabidiol (Can-a-bid-i-ol), a prominent naturally occurring class of molecules called cannabinoids found in the plant genus Cannabis Sativa L. CBD comprises up to 40% of the plant and is one of over 60 plus compounds found in cannabis. Of these compounds, CBD and THC are usually present in the highest concentrations, and are therefore the most recognized and studied. CBD is a non- psychoactive component of the plant that possesses a wide range of benefits and does not cause a high, unlike THC. Our bodies are made up of an endocannabinoid system and use cannabinoids to maintain healthy cells.
Nabiximols (brand name Sativex) is a patented medicine containing CBD and THC in equal proportions. The drug was approved by Health Canada in 2005 for prescription to treat central neuropathic pain in multiple sclerosis, and in 2007 for cancer related pain. In New Zealand Sativex® is approved for use as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to Multiple Sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.